Mission Wealth Management’s Novavax NVAX Stock Holding History

Mission Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-39,000	Closed	-$493K	–	704
2024 Q3	$493K	Hold	39,000	–	–	0.01%	433
2024 Q2	$494K	Buy	+39,000	New	+$392K	0.01%	413

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Mission Wealth Management's NVAX Position: Q4 2024 in Review

Mission Wealth Management sold out of Novavax (NVAX) in Q4 2024, closing a stake of 39,000 shares — an estimated $493K sold.

Mission Wealth Management first reported a position in NVAX in Q2 2024 and held it in 2 quarters. The position peaked at $494K in Q2 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

Mission Wealth Management reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
Mission Wealth Management sold 39,000 Novavax shares in Q4 2024, an estimated $493K.
Mission Wealth Management first reported a position in Novavax in Q2 2024 and held it in 2 quarters.
Mission Wealth Management's Novavax position peaked at $494K in Q2 2024.
234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Mission Wealth Management's 13F filing for Q4 2024, filed 6 Feb 2025.